Additionally, in hematological malignancies, the ROCK-regulated actomyosin cytoskeleton contributes to the survival and growth of TK-driven malignancies; thus, ROCK inhibitors can be used as effective therapeutics either by themselves or in combination with other TKIs for the treatment of oncogenic TK-driven malignancies [23]. This evidence concerns the gene TKT and cancer.